Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity

Completed · Phase 2

Conditions studied: Stroke

In brief

The purpose of this study is to assess prospectively the efficacy of hydroxyurea therapy in the setting of cerebrovascular disease, manifest as conditional or abnormal transcranial doppler ultrasonography (TCD) flow velocities, in children with sickle cell anemia (SCA). TCD is used to measure flow velocity in intracranial arteries as a marker of increased stroke risk in children with SCA. The primary objective of this protocol is to determine whether hydroxyurea reduces elevated TCD velocity.

Key facts

Study ID

NCT00402480

Run by

Duke University

People needed

50

Starts

2003-04-01

Expected to finish

2006-03-01

Last updated by the study team

2013-06-19

Who can join

Age: 3 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Children with Sickle Cell Anemia
• Aged 3 to 18 years
• Confirmed TCD velocity greater than or equal to 140cm/sec
• Negative serum pregnancy test for subjects of childbearing potential
• Decline transfusions (for subjects with TCD velocity greater than or equal to 200 cm/sec)

Where it is running

• Duke University Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.